Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study

BACKGROUND: Several antidiabetic drugs (i.e., sulfonylureas; SU, rosiglitazone) have been reported to be associated with increased risks of cardiovascular diseases (CVD) in patients with type 2 diabetes mellitus (T2DM). Dipeptidyl peptidase-4 inhibitors (DPP4i) are newly available antidiabetic drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Huang-Tz, Chang, Kai-Cheng, Li, Chung-Yi, Wu, Jin-Shang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774127/
https://www.ncbi.nlm.nih.gov/pubmed/26932742
http://dx.doi.org/10.1186/s12933-016-0350-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774127/
https://www.ncbi.nlm.nih.gov/pubmed/26932742
http://dx.doi.org/10.1186/s12933-016-0350-4

Ejemplares similares